India adds another 89,706 cases, tally at 4370129
New Delhi, Sep 9: India on Wednesday not only recorded 89,706 fresh COVID-19 cases and 1,115 more deaths, but also received a setback as Oxford vaccine phase III clinical trials were put on hold after a participant in UK reportedly developed an adverse reaction.
Leading pharmaceutical company AstraZeneca said the nature of the suspected serious adverse reaction was not immediately known.
The vaccine being developed by AstraZeneca in partnership with the Oxford University’s Jenner Institute and the Oxford Vaccine Group is in phase 3 trials, which is the final stage before safety and efficacy data can be submitted to health regulators for approval.
As per an update from Union Health Ministry, the total number of COVID-19 cases reached 43,70,129, highest number outside United States, while the death toll surged to 73,890.
There are as many as 8,97,394 active cases while recovered stand at 33,98,844. The recovery rate has reached 77.77 per cent while the fatality rate stands at 1.69 per cent.
Some 11,54,549 samples were tested in the past 24 hours, according to the Indian Council of Medical Research (ICMR)
Maharashtra continued to top the charts, registering 6,517 fresh cases, taking the tally to 9,43,772, while the death toll reached 27,407, after 380 more people succumbed to the virus.
At next, Andhra Pradesh has so far registered 5,17,094 cases and 4,560 deaths. As many as 10,600 cases and 73 deaths were recorded in the past 24 hours.
Tamil Nadu registered 5,776 fresh cases, taking the total number of cases to 4,69,256, while the death toll reached 7,925, after 89 people died.
Meanwhile, the Centre have decided to reopen schools which are closed since March. As per the guidelines students from IX to XII standard can go to school for taking guidance from the teachers but only after taking consent from the parents.